The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours. It is important that the study medication, YM872 or placebo, is administered prior to the completion of the t-PA administration. The clinical effects of YM872 in addition to t-PA will be determined by assessing neurological function and disability scores at follow up visits through Day 90 of the study.
- Tissue plasminogen activator (Activase®)Drug
Other Names: Alteplase; tPA Intervention Desc: Thrombolytic
- YM872 Drug
Intervention Desc: Glutamate blocker, AMPA receptor antagonist
- YM872 (zonampanel), t-PA (alteplase) Drug
- Allocation: Randomized
- Masking: Double-Blind
- Purpose: Treatment
Eligible patients will be randomized to receive a either a 24-hour infusion of YM872 or of placebo. All patients will receive standard infusions of tPA within 3 hours of stroke onset, and will be followed-up at 90 days.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Efficacy will be measured using neurological function and disability scales.|